← Special Reports
HaematologyLymphoma

Diffuse Large B-Cell Lymphoma: Frontline Immunotherapy Arrives

R-CHOP has been standard of care for 20 years. frontMIND may be the beginning of the end

SR-2026-013
EditorMara Voss
CopywritersEditorial Team
Coming Soon

Diffuse Large B-Cell Lymphoma: Frontline Immunotherapy Arrives

R-CHOP has been standard of care for 20 years. frontMIND may be the beginning of the end

Why We Are Covering This

The frontMIND trial at ASCO 2026 established that adding tafasitamab to R-CHOP improves outcomes in newly diagnosed high-risk DLBCL, marking the first major advance in frontline treatment in over a decade.

What to Expect

You will leave knowing how frontMIND data integrates with current practice, how to sequence CAR-T and bispecifics in relapsed disease, and what approval timelines to expect for frontline CD19-directed therapy.

Be first when this report publishes

The Life Science Feed briefing covers every major trial readout, approval, and pipeline shift, weekly.

Get the briefing first
The Life Science Feed
thelifesciencefeed.com · Special Report
SR-2026-01307/26

Related Articles

Liso-Cel Delivers Durable OS Benefit in R/R LBCL, Redefining TreatmentLymphoma

Liso-Cel Delivers Durable OS Benefit in R/R LBCL, Redefining Treatment

Lisocabtagene maraleucel (liso-cel) significantly extended overall survival in relapsed/refractory large B-cell lymphoma, establishing a new benchmark for second-line therapy.

11 min readGet the full story
Monoclonal Antibodies May Complicate Transfusion TestingImmune Thrombocytopenia

Monoclonal Antibodies May Complicate Transfusion Testing

Monoclonal antibodies, particularly IgG4 anti-CD47, may induce erythrophagocytosis and interfere with transfusion compatibility testing, posing a challenge for patient management.

7 min readGet the full story
Blood Transfusion Safety: Pathogen Inactivation Reduces Transfusion-Transmitted InfectionsSickle Cell Disease

Blood Transfusion Safety: Pathogen Inactivation Reduces Transfusion-Transmitted Infections

Modern blood transfusion practices, including pathogen inactivation, have significantly reduced the risk of transfusion-transmitted infections, improving patient safety.

7 min readGet the full story
Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)Leukemia
EHA 2026

Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)

Chemotherapy-free regimens for pediatric acute promyelocytic leukemia (APL) demonstrate superior efficacy and reduced toxicity compared to traditional chemotherapy.

8 min readGet the full story
    0:00 / 0:00